AUVI - Applied UV and 3Sixty Biopharmaceuticals ink exclusive distribution agreement

Applied UV (AUVI) announces the signing of an exclusive distribution agreement with 3Sixty Biopharmaceuticals for Airocide consumer and commercial air purification systems.Under the terms of the agreement, 3Sixty has agreed to an upfront binding purchase commitment of a minimum of $3.5M of Airocide systems over the initial one-year term of the agreement.After the initial term, both parties have agreed to assess opportunities to expand the product line to include the SteriLumen platform of connected UVC devices for infection control in and around high-traffic areas.Applied UV shares up more than 2% premarket.

For further details see:

Applied UV and 3Sixty Biopharmaceuticals ink exclusive distribution agreement